Amenamevir
Allopathic
Share this page
Indications
Approved Indications
- Treatment of Herpes Zoster (Shingles) in adults caused by Varicella-Zoster Virus (VZV).
Off-Label / Clinically Accepted Uses
- Limited clinical and investigational use in Herpes Simplex Virus (HSV-1 and HSV-2) infections.
Dosage & Administration
Adults
- 400 mg orally once daily after meals for 7 days
- Treatment should be started as early as possible, preferably within 72 hours of rash onset.
Pediatrics
- Safety and efficacy have not been established in pediatric patients.
Elderly
- No specific dosage adjustment generally required.
- Clinical monitoring is recommended.
Special Populations
- Renal impairment: Use with caution in severe renal dysfunction.
- Hepatic impairment: Use cautiously in moderate to severe hepatic impairment.
Administration
- Route: Oral
- Take after meals.
Mechanism of Action (MOA)
Amenamevir inhibits the viral helicase-primase complex, an enzyme essential for herpesvirus DNA replication. This action suppresses viral multiplication and helps reduce the severity and duration of herpes zoster infection.
Pharmacokinetics
- Absorption: Rapidly absorbed after oral administration.
- Distribution: Highly protein bound (>95%).
- Metabolism: Primarily metabolized in the liver via CYP3A enzymes.
- Excretion: Mainly eliminated through feces; minor urinary excretion.
- Half-life: Approximately 7–8 hours.
Pregnancy Category & Lactation
Pregnancy
- Limited human safety data available.
- Use only if the potential benefit justifies the potential risk.
Lactation
- It is unknown whether amenamevir is excreted in human breast milk.
- Caution is advised during breastfeeding.
Therapeutic Class
Antiviral Agent (Helicase-Primase Inhibitor)
Contraindications
- Known hypersensitivity to amenamevir or any component of the formulation.
Warnings & Precautions
- Use cautiously in patients with hepatic impairment.
- Concomitant use with strong CYP3A inducers or inhibitors may alter drug levels.
- Early initiation of treatment improves clinical outcome.
Side Effects
Common
- Headache
- Nausea
- Diarrhea
- Constipation
- Abdominal discomfort
Serious
- Hypersensitivity reactions
- Elevated liver enzymes
Drug Interactions
- CYP3A inducers (e.g., rifampicin, carbamazepine) may reduce effectiveness.
- CYP3A inhibitors may increase plasma concentration.
- Use cautiously with drugs metabolized by CYP3A enzymes.
Recent Updates / Guidelines
Amenamevir is approved in Japan for herpes zoster treatment and is recognized as a novel antiviral with a unique helicase-primase inhibition mechanism.
Chemical Structure
- Molecular Formula: C24H25N5O3
- Molecular Weight: 431.49 g/mol
Storage Conditions
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.